A phase I/II open-label, dose-escalation study to determine the maximum tolerated dose and to evaluate the safety profile of lenalidomide (Revlimid) with liposomal doxorubicin in subjects with advanced ovarian and primary peritoneal carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 11 Apr 2006
At a glance
- Drugs Doxorubicin liposomal; Lenalidomide
- Indications Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 29 Oct 2005 New trial record.